$44.70
1.80% yesterday
Nasdaq, Dec 02, 10:00 pm CET
ISIN
US92243G1085
Symbol
PCVX

Vaxcyte Inc Stock price

$44.70
+1.87 4.37% 1M
+9.68 27.64% 6M
-37.16 45.39% YTD
-46.90 51.20% 1Y
-0.21 0.47% 3Y
+13.41 42.86% 5Y
+18.55 70.94% 10Y
+18.55 70.94% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.82 1.80%
ISIN
US92243G1085
Symbol
PCVX
Industry

Key metrics

Basic
Market capitalization
$5.9b
Enterprise Value
$4.1b
Net debt
positive
Cash
$1.7b
Shares outstanding
130.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
94.2%
Return on Equity
-14.0%
ROCE
-27.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-806.7m | $-791.0m
EBIT
$-811.6m | $-846.2m
Net Income
$-657.2m | $-672.9m
Free Cash Flow
$-620.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-36.4% | -40.6%
EBIT
-34.5% | -48.6%
Net Income
-29.4% | -45.1%
Free Cash Flow
-0.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.8
FCF per Share
$-4.8
Short interest
8.0%
Employees
414
Rev per Employee
$0.0
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Vaxcyte Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Vaxcyte Inc forecast:

Buy
88%
Hold
12%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 126 126
54% 54%
-
- Research and Development Expense 686 686
53% 53%
-
-807 -807
36% 36%
-
- Depreciation and Amortization 4.84 4.84
59% 59%
-
EBIT (Operating Income) EBIT -812 -812
34% 34%
-
Net Profit -657 -657
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Neutral
GlobeNewsWire
28 days ago
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study
Neutral
GlobeNewsWire
2 months ago
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates
Neutral
Seeking Alpha
3 months ago
Vaxcyte, Inc. (NASDAQ:PCVX ) Cantor Global Healthcare Conference 2025 September 3, 2025 2:45 PM EDT Company Participants Grant Pickering - Co-Founder, CEO & Director Andrew Guggenhime - President & CFO James Wassil - Executive VP & COO Conference Call Participants Carter Gould - Cantor Fitzgerald & Co., Research Division Presentation Carter Gould Research Analyst Okay. Good afternoon.
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 414
Founded 2013
Website vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today